Skip to content

OZEMRoundhill Glp-1 & Weight Loss ETF

Grow my money2y track recordRanked #1,840 of 2,960 in this goal

Seeks to provide capital appreciation.

By Roundhill Investments · Launched 2024

Annual Cost

0.59%

#3,001 of 5,562 · average

Fund Size

$50M

#3,571 of 5,562 · mid-size

Return (1Y)Goal

+19.4%

Track Record

2 years

#3,578 of 5,562 · seasoned

Performance

Total-return NAV · USD
Growth of $10,000
$11,821+18.2%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Cap

Multi cap

Strategy

Active selection

Focus

Obesity & GLP-1

What it actually holds

By weight

Concentration

Top 10 holdings = 69.5% of fundconcentrated

Novo Nordisk A/S
19.7%
Eli Lilly & Co
16.0%
Mount Vernon Liquid Assets Portfolio, LLC
5.0%
Zealand Pharma A/S
4.5%
Viking Therapeutics Inc
4.4%
Roche Holding AG
4.2%
Structure Therapeutics Inc
4.1%
Pfizer Inc
4.0%
Chugai Pharmaceutical Co Ltd
4.0%
Amgen Inc
3.6%

Asset allocation

Stocks
99.7%
Other
0.3%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
24.0%High

Year-on-year price swings

Max drawdown
-28.6%Moderate

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Where to buy

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks to provide capital appreciation.
Strategy
Actively managed ETF focusing on companies developing GLP-1 & Weight Loss Drugs. Invests primarily in equity securities of leading firms in clinical trials or FDA-approved drugs, with a concentration in the health care sector.
Inception date
May 20, 2024
Fund family
Roundhill Investments

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Thematic
Warning

Thematic ETF — launched after the rally

Thematic funds are typically launched after a theme has delivered its strong returns. Morningstar's 2024 Global Thematic Funds Landscape finds that only about 1 in 10 thematic funds have survived and beaten a broad global equity benchmark over the past 15 years — roughly 60% have been closed outright. The narrative is always compelling; the track record rarely is.

Source: Morningstar, 'Global Thematic Funds Landscape' (2024)

Why we flagged this: Narrow thematic name, launched in the last 3 years, $50M in assets (under our $500M threshold).

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've reviewed OZEM. Save it to your watchlist to track it alongside the other funds you're weighing.

Data updated on 2026-06-19